ATM is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 5 clinical trials for colorectal adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRAF status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (0 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DPYD is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DPYD status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for colorectal adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and colorectal adenocarcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 12 clinical trials for colorectal adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain KRAS status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (6 open), and 2 are phase 3 (2 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 8 clinical trials for colorectal adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain NRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

UGT1A1 is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain UGT1A1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].